Oticon Intent vs Otofonix Groove

The Oticon Intent is a premium behind-the-ear prescription hearing aid released in 2024, priced at $4,898. With a SoundScore of 4.8/5 and an A grade, it ranks #3 among the 36 prescription hearing aids tested by HearAdvisor, placing it in the top 6% of its category. In our lab testing, the Intent delivers strong speech performance, scoring 1.10 points above the category average for speech in noise and 0.62 points above average for speech in quiet. Music streaming is a particular strength at 4.0/5, which is 1.36 points above the prescription hearing aid average—making it a solid choice for users who frequently stream audio from their phones. Feedback handling is excellent at 5.0/5, ensuring stable performance without whistling during everyday activities. The most notable limitation is own-voice comfort, which scores 1.3/5—a low result that falls 1.45 points below the category average. Users sensitive to how their own voice sounds while wearing hearing aids should be aware of this trade-off. The Intent includes rechargeable batteries, both iPhone and Android streaming, and hands-free calling capabilities. It has earned HearAdvisor's Expert's Choice Award in both 2023 and 2024. This hearing aid is best suited for users prioritizing speech clarity in challenging listening environments and high-quality audio streaming, who can accept the own-voice characteristics. Within its premium price tier, competitors like the Phonak Sphere Infinio (5.0/5) and Oticon Real (4.75/5) offer alternatives worth considering.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE device ranks 36th out of 36 tested prescription hearing aids, placing it in the bottom tier of its category. In our testing, the Groove demonstrated one clear strength: excellent feedback handling at 5.0/5, scoring 0.29 points above the category average. The device remained stable during our standardized challenge motions with no audible feedback issues. However, speech performance was significantly limited, with both speech in quiet and speech in noise scoring 1.0/5—falling 2.32 and 0.96 points below their respective category averages. Music streaming quality scored 0.0/5, which is 2.64 points below the prescription category average. Own-voice comfort was also low at 0.4/5 in the tuned configuration, 2.35 points below average, suggesting notable occlusion-related concerns. The normalized Initial Score of 2.7/5 and Tuned Score of 2.6/5 indicate that professional fitting adjustments did not improve overall performance. Given its positioning at the bottom of the prescription hearing aid category and the availability of lower-priced alternatives that scored higher in our testing, the Otofonix Groove may be difficult to recommend for most users seeking balanced sound quality across listening situations.